key: cord-0683447-8akrxiyl
authors: Gondo, G.C.; Bell, S.J.; Slayden, J.; Ullmann, G.; Blauvelt, A.
title: Concerns and perceptions of patients with psoriatic disease during the COVID‐19 pandemic: results from a two‐wave survey by the National Psoriasis Foundation
date: 2021-03-02
journal: J Eur Acad Dermatol Venereol
DOI: 10.1111/jdv.17173
sha: fa223d26c1b5de0ee9e74b6654dc1ccacb027e43
doc_id: 683447
cord_uid: 8akrxiyl

Rapid online surveys may help illuminate patient perspectives about the SARS-COV-2 virus and the COVID-19 pandemic, allowing clinicians to address these concerns.(1) To understand patient perspectives during the early phases of the COVID-19 pandemic, the National Psoriasis Foundation (NPF) conducted a two-wave survey of a random stratified sample of individuals 18 years of age or older with psoriatic disease in the United States who recently contacted the NPF.

Editor, Rapid online surveys may help illuminate patient perspectives about the SARS-COV-2 virus and the COVID-19 pandemic, allowing clinicians to address these concerns. 1 To understand patient perspectives during the early phases of the COVID-19 pandemic, the National Psoriasis Foundation (NPF) conducted a two-wave survey of a random stratified sample of individuals 18 years of age or older with psoriatic disease in the United States who recently contacted the NPF. In April and June 2020, the following questions assessed patient perspectives (IRBapproved by Genetic Alliance):

• How concerned are you ( • How much of a threat, if any, do you feel the COVID-19 pandemic represents to your personal health? (1, not at all -5, extremely serious threat). Of the 8398 surveys sent out, 263 were completed. Respondents were mostly female (84%) and white (88%), older (mean age = 53.6), 57.8% with PsO/PsA, 4.9% with PsA alone, 37.3% with PsO alone, and 54.4% had previously used biologics. Few reported their HCP discussed the impact of having PsO/PsA (18.6%) or PsO/PsA treatments (20.2%) on COVID-19 infection risk. Increased perception of COVID-19 as a threat to personal health was associated with disease type but not treatment type. Individuals with PsA perceived COVID-19 as a higher threat to their personal health than patients with PsO alone (baseline F(1, 259) = 7.12, P < 0.05, and follow-up • Worsen outcomes if infected due to PsO/PsA or its treatments?(M = 3.10, SD = 1.51 to M = 2.85, SD = 1.55, t(263) = 3.04, P ≤ 0.001; paired samples t-test). In summary, in two surveys administered early in the COVID-19 pandemic, US patients with psoriatic disease reported that few COVID-19-related discussions had occurred between them and their HCP. Respondents with PsA and biologic users reported a greater concern that treatments increase risk of SARS-CoV-2 infection and may cause worse COVID-19 outcomes. These survey results resemble comparable studies, [2] [3] [4] suggesting patients are concerned how treatments and disease status may influence risk of COVID-19 infection and outcomes. Guidance on managing psoriatic disease during the COVID-19 pandemic published by the NPF may improve patient-provider communication about these important topics. 5, 6 Low-survey completion rate and a sample consisting of individuals engaged with a patient advocacy organization may contribute to selection bias. The COVID-19 pandemic could have increased barriers to e-mail communication, contributing to the lack of communication between patients and HCPs. Treatment status was also not objectively defined. Lastly, survey items had not undergone psychometric testing, and the survey sample may not be representative of the estimated psoriatic patient population.

The studies were funded by the National Psoriasis Foundation.

Use of rapid online surveys to assess people's perceptions during infectious disease outbreaks: a cross-sectional survey on COVID-19

Experiences of patients with rheumatic diseases in the united states during early days of the COVID-19 pandemic

Awareness, attitudes, and actions related to COVID-19 among adults with chronic conditions at the onset of the U.S. outbreak: a cross-sectional survey

Perspectives of patients with rheumatic diseases in the early phase of COVID-19

National psoriasis foundation COVID-19 task force guidance for management of psoriatic disease during the pandemic: version 1

National Psoriasis Foundation COVID-19 task force guidance for management of psoriatic disease during the pandemic: version 2 -advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments